185 related articles for article (PubMed ID: 2788716)
1. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Longo DL; Glatstein E; Duffey PL; Ihde DC; Hubbard SM; Fisher RI; Jaffe ES; Gilliom M; Young RC; DeVita VT
J Clin Oncol; 1989 Sep; 7(9):1295-302. PubMed ID: 2788716
[TBL] [Abstract][Full Text] [Related]
2. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
[TBL] [Abstract][Full Text] [Related]
3. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
4. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young RC; Longo DL; Glatstein E; Ihde DC; Jaffe ES; DeVita VT
Semin Hematol; 1988 Apr; 25(2 Suppl 2):11-6. PubMed ID: 2456618
[TBL] [Abstract][Full Text] [Related]
5. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
6. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
7. ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher RI; Young RC; Longo D; DeVita VT
Semin Oncol; 1985 Mar; 12(1 Suppl 2):29-32. PubMed ID: 2579441
[TBL] [Abstract][Full Text] [Related]
8. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. Hematologic malignancies: non-Hodgkin's lymphomas.
DeVita VT
Hosp Pract (Off Ed); 1986 Sep; 21(9):103-18. PubMed ID: 2427535
[No Abstract] [Full Text] [Related]
11. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
12. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
13. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher RI; DeVita VT; Hubbard SM; Longo DL; Wesley R; Chabner BA; Young RC
Ann Intern Med; 1983 Mar; 98(3):304-9. PubMed ID: 6600902
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
16. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
Chen YC; Ho CL; Kao WY; Hwang JM; Sheu LF; Chao TY
Ann Hematol; 2001 Nov; 80(11):647-52. PubMed ID: 11757723
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy of malignant lymphoma].
Horikoshi N; Ogawa M
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1903-10. PubMed ID: 6985187
[TBL] [Abstract][Full Text] [Related]
18. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L
Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334
[TBL] [Abstract][Full Text] [Related]
19. [Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives].
Bron D; Vandenheule B; Stryckmans P
Rev Med Brux; 1985 Sep; 6(7):491-5. PubMed ID: 2417298
[No Abstract] [Full Text] [Related]
20. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.
Dent S; Eapen L; Girard A; Hugenholtz H; DaSilva V; Stewart DJ
J Neurooncol; 1996 Apr; 28(1):25-30. PubMed ID: 8740588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
